New drug combo tested against rare, Tough-to-Treat cancers
NCT ID NCT03074513
Summary
This study is testing whether a combination of two immunotherapy drugs, atezolizumab and bevacizumab, can help control several rare types of advanced solid tumors. The trial is for adults whose cancer has spread or returned after other treatments. The goal is to see if this drug pair can help the body's immune system fight the cancer and slow its growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.